Involved-field radiotherapy: a potential standard therapy for early stage LPHL
Alexandra King
This article has no abstract so we have provided the first paragraph of the full text.
There have been very few clinical studies of patients with early-stage lymphocyte-predominant Hodgkin's lymphoma (LPHL), because of the low incidence of this malignancy. Therefore, to date, no standard treatment has been established; therapeutic options include extended-field (EF) and involved-field (IF) radiotherapy, and combined modality (CM) approaches. In response to this lack of standard treatment, the German Hodgkin Study Group has recently published a retrospective analysis of its response, survival, and toxicity data for different treatment options in patients with stage IA LPHL without risk factors.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.